Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Other Non-Current Liabilities (2020 - 2022)

Historic Other Non-Current Liabilities for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q3 2022 value amounting to $5.2 million.

  • Atea Pharmaceuticals' Other Non-Current Liabilities changed N/A to $5.2 million in Q3 2022 from the same period last year, while for Sep 2022 it was $5.2 million, marking a year-over-year change of. This contributed to the annual value of $5.9 million for FY2021, which is 1637777.78% up from last year.
  • Per Atea Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $5.2 million for Q3 2022.
  • In the past 5 years, Atea Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $6.0 million in Q2 2022 and a low of $29000.0 during Q2 2021
  • Over the past 3 years, Atea Pharmaceuticals' median Other Non-Current Liabilities value was $2.6 million (recorded in 2021), while the average stood at $2.9 million.
  • The largest annual percentage gain for Atea Pharmaceuticals' Other Non-Current Liabilities in the last 5 years was 2061724.14% (2022), contrasted with its biggest fall of 514955.75% (2022).
  • Atea Pharmaceuticals' Other Non-Current Liabilities (Quarter) stood at $36000.0 in 2020, then surged by 16377.78% to $5.9 million in 2021, then fell by 12.85% to $5.2 million in 2022.
  • Its Other Non-Current Liabilities stands at $5.2 million for Q3 2022, versus $6.0 million for Q2 2022 and $5.9 million for Q1 2022.